DDInter1388 DDInter1435
Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Pantoprazole {u} (Compound) binds {v} (Gene) ATP4B
Pantoprazole {u} (Compound) upregulates {v} (Gene) TCTN1
Pantoprazole {u} (Compound) downregulates {v} (Gene) ACAT2
Pantoprazole {u} (Compound) causes {v} (Side Effect) Jaundice cholestatic
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capmatinib
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cefditoren
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Pantoprazole {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Pantoprazole (Compound) resembles Omeprazole (Compound)
Pantoprazole (Compound) binds ATP4B (Gene)
Pantoprazole (Compound) upregulates TCTN1 (Gene)
Pantoprazole (Compound) downregulates ACAT2 (Gene)
Pantoprazole (Compound) causes Jaundice cholestatic (Side Effect)
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Pantoprazole may lead to a major life threatening interaction when taken with Atazanavir